[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334887-105":59,"doc-detail-334887-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-phase-i-trial-of-nab-paclitaxelbevacizumab-ab160-nano-immunoconjugate-therapy-for-gynecologic-malignancies","A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies","","Antibody–drug conjugates face limited clinical selectivity and narrow therapeutic windows, driving risks of normal-tissue toxicity and dose reductions. This phase I study evaluates AB160, a 160-nm nano-immunoconjugate of nab-paclitaxel nanoparticles coated with bevacizumab for VEGF-targeted delivery. In previously treated endometrial, cervical, and platinum-resistant ovarian cancer, AB160 was given on days 1, 8, and 15 of 28-day cycles to define the recommended phase II dose.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-phase-i-trial-of-nab-paclitaxelbevacizumab-ab160-nano-immunoconjugate-therapy-for-gynecologic-malignancies/334887/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-phase-i-trial-of-nab-paclitaxelbevacizumab-ab160-nano-immunoconjugate-therapy-for-gynecologic-malignancies/334887.png","ImageObject",300,407,{"name":92,"@type":93},"Hazel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is AB160 and what is its intended targeting mechanism?","Question",{"text":112,"@type":113},"AB160 is a 160-nm nano-immunoconjugate combining nab-paclitaxel nanoparticles coated with bevacizumab to support targeted delivery into tissues expressing high levels of VEGF.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What patient populations were included in this phase I trial?",{"text":117,"@type":113},"The study enrolled patients with previously treated endometrial, cervical, and platinum-resistant ovarian cancer.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes supported the trial’s recommended phase II dose?",{"text":121,"@type":113},"No dose-limiting toxicities were observed across three dose levels, and DL2 (ABX 150 mg/m2, BEV 60 mg/m2) was selected as the recommended phase II dose, alongside evidence of confirmed partial responses and favorable pharmacokinetics.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334887,1790144636,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies  \nEleftheria Kalogera1, Wendy K. Nevala2, Heidi D. Finnes3, Vera J. Suman4, Jill M. Schimke5, Carrie A. Strand4, Lisa A. Kottschade5, Rachel A. Kudgus5, Sarah A. Buhrow5, Laura R. Becher2, Liyi Geng2, Gretchen E. Glaser1, Megan E. Grudem5, Aminah Jatoi5, Carolyn M. Klampe5, Amanika Kumar1, Carrie L. Langstraat1, Robert R. McWilliams5, Andrea E. Wahner Hendrickson5, S. John Weroha5, Yiyi Yan5, Joel M. Reid5, Svetomir N. Markovic2,5, and Matthew S. Block5  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: AB160 is a 160-nm nano-immunoconjugate consisting of nab-paclitaxel (ABX) nanoparticles noncovalently coated with bevacizumab (BEV) for targeted delivery into tissues expressing high levels of VEGF. Preclinical data showed that AB160 resulted in greater tumor targeting and tumor inhibition compared with sequential treatment with ABX then BEV. Given individual drug activity, we investigated the safety and toxicity of AB160 in patients with gynecologic cancers.\u003Cbr>Patients and Methods: A 3+3 phase I trial was conducted with three potential dose levels in patients with previously treated endometrial, cervical, and platinum-resistant ovarian cancer to ascertain the recommended phase II dose (RP2D) . AB160 was administered intravenously on days 1, 8, and 15 of a 28-day cycle\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (ABX 75–175 mg/m2, BEV 30–70 mg/m2). Pharmacokinetic analyses were performed.\u003Cbr>Results: No dose-limiting toxicities (DLT) were seen among the three dose levels tested. Grade 3/4 toxicities included neutropenia, thromboembolic events, and leukopenia. DL2 (ABX 150 mg/m2, BEV 60 mg/m2) was chosen as the RP2D. Seven of the 19 patients with measurable disease (36.8%) had confirmed partial responses (95% confidence interval, 16.3%–61.6%). Pharmacokinetic analyses demonstrated that AB160 allowed 50% higher paclitaxel dosing and that paclitaxel clearance mirrored that of therapeutic antibodies.\u003Cbr>Conclusions: The safety profile and clinical activity of AB160 supports further clinical testing in patients with gynecologic cancers; the RP2D is DL2 (ABX 150 mg/m2, BEV 60 mg/m2) . |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nAntibody–drug conjugates (ADC) represent an attractive approach for systemic therapy of disseminated cancer (1). Although standard chemotherapy remains the mainstay treatment for most disseminated malignancies, its use is limited by the lack of sufficient selectivity for cancer cells that translates clinically as normal tissue toxicity. The resultant narrow therapeutic window limits physicians’ ability to administer sufficient doses to achieve maximum therapeutic benefit while at the same time minimizing toxicity. In clinical practice, this translates into dose reductions, treatment interruptions, or even treatment ","cbCairH9fNICnGKM","https://ap.wps.com/l/cbCairH9fNICnGKM","pdf",3175829,13,"English","# Purpose\n## Patients and Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What is AB160 and what is its intended targeting mechanism?\",\"answer\":\"AB160 is a 160-nm nano-immunoconjugate combining nab-paclitaxel nanoparticles coated with bevacizumab to support targeted delivery into tissues expressing high levels of VEGF.\"},{\"question\":\"What patient populations were included in this phase I trial?\",\"answer\":\"The study enrolled patients with previously treated endometrial, cervical, and platinum-resistant ovarian cancer.\"},{\"question\":\"What outcomes supported the trial’s recommended phase II dose?\",\"answer\":\"No dose-limiting toxicities were observed across three dose levels, and DL2 (ABX 150 mg/m2, BEV 60 mg/m2) was selected as the recommended phase II dose, alongside evidence of confirmed partial responses and favorable pharmacokinetics.\"}]","A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies | PDF",1790008746,33]